Following our exploration of competitive regional preferences for NGS tools, we've delved deeper into the pivotal role of reimbursements. 3 key findings:
1) Full coverage and evidence-based coverage are gaining traction, even for expansive sequencing like WES and WGS. The majority of NGS panels achieve successful private payer reimbursement. This trend highlights the increasing endorsement of NGS technology in healthcare.
2) While the U.S. enjoys a favorable private payer landscape, across panel sizes, the EU tends to be more cautious. Large panels often face reimbursement challenges, with only ~25% success.
3) As we look ahead, concerns about reimbursement seem to be fading. Labs planning NGS adoption don't view reimbursement as a barrier to the same extent they did a few years ago.
Reimbursement isn't just about money; it reflects healthcare priorities, research advances, and the drive to provide cutting-edge care to patients.
Want a deep dive into these reimbursement patterns? Reach out to Julia and Rishikesh! And swipe for more detailed! #NGSisUnstoppable
.png)
.png)
